
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Ocular Therapeutix Inc (OCUL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: OCUL (4-star) is a STRONG-BUY. BUY since 25 days. Profits (30.38%). Updated daily EoD!
1 Year Target Price $17.92
1 Year Target Price $17.92
6 | Strong Buy |
6 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 171.41% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio - | 1Y Target Price 17.92 |
Price to earnings Ratio - | 1Y Target Price 17.92 | ||
Volume (30-day avg) 12 | Beta 1.41 | 52 Weeks Range 5.79 - 11.78 | Updated Date 07/12/2025 |
52 Weeks Range 5.79 - 11.78 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -597.47% |
Management Effectiveness
Return on Assets (TTM) -27.21% | Return on Equity (TTM) -57.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1483619088 | Price to Sales(TTM) 29.46 |
Enterprise Value 1483619088 | Price to Sales(TTM) 29.46 | ||
Enterprise Value to Revenue 24.87 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 159300000 | Shares Floating 122343790 |
Shares Outstanding 159300000 | Shares Floating 122343790 | ||
Percent Insiders 3.82 | Percent Institutions 87.01 |
Upturn AI SWOT
Ocular Therapeutix Inc

Company Overview
History and Background
Ocular Therapeutix, Inc. was founded in 2006. It's a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel platform technology. Significant milestones include the FDA approval and commercialization of DEXTENZAu00ae for post-surgical ocular inflammation and its pipeline of other ophthalmic drug candidates.
Core Business Areas
- Commercial Products: DEXTENZAu00ae for the treatment of ocular inflammation and pain following ophthalmic surgery. Also offering ReSureu00ae Sealant, although the revenues from this product is lower.
- Pipeline Development: Developing a portfolio of sustained-release drug candidates for various ophthalmic conditions, including glaucoma, dry eye disease, and retinal diseases.
Leadership and Structure
The leadership team consists of key executives such as the CEO, CFO, and Chief Medical Officer. The organizational structure includes departments for research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- DEXTENZA: DEXTENZAu00ae is a corticosteroid insert placed in the punctum (tear duct) of the eye following cataract surgery to treat post-operative inflammation and pain for up to 30 days. It aims to improve patient compliance and reduce the need for frequent eye drops. Market share data is growing but still a smaller percentage. Competitors include generic steroid eye drops and other branded eye drops like PROLENSAu00ae (bromfenac ophthalmic solution) 0.07% and ILEVROu00ae (nepafenac ophthalmic suspension) 0.3%.
- ReSure Sealant: ReSure Sealant is a hydrogel sealant applied to corneal incisions to prevent wound leaks following cataract surgery. Revenues from ReSure are lower than Dextenza. Main competitors are other methods of wound closure like sutures.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is characterized by increasing prevalence of eye diseases, an aging population, and technological advancements in treatment options. Key areas of focus include treatments for glaucoma, dry eye, macular degeneration, and post-operative care.
Positioning
Ocular Therapeutix is positioned as an innovator in sustained-release ophthalmic drug delivery. Its bioresorbable hydrogel technology offers a competitive advantage by providing controlled and prolonged drug release, potentially improving patient adherence and outcomes.
Total Addressable Market (TAM)
The global ophthalmic drug market is estimated to be substantial, with some estimates projecting it to exceed $40 billion in the coming years. Ocular Therapeutix is positioned to capture a segment of this market by addressing unmet needs in post-operative care and chronic eye diseases.
Upturn SWOT Analysis
Strengths
- Proprietary bioresorbable hydrogel technology
- FDA-approved product (DEXTENZAu00ae)
- Strong intellectual property portfolio
- Potential for improved patient compliance with sustained-release delivery
Weaknesses
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Reliance on a single key product (DEXTENZAu00ae) for revenue
- Ongoing need for capital to fund research and development
- Manufacturing complexities associated with bioresorbable hydrogel
Opportunities
- Expansion of DEXTENZAu00ae label to other indications
- Development of new sustained-release therapies for chronic eye diseases
- Strategic partnerships with larger pharmaceutical companies
- Increasing awareness of the benefits of sustained-release drug delivery
Threats
- Competition from generic and branded ophthalmic drugs
- Regulatory hurdles and clinical trial risks
- Pricing pressures from healthcare payers
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- ALC (Alcon)
- JNJ (Johnson & Johnson)
- VRX (Bausch Health)
Competitive Landscape
Ocular Therapeutix's advantage lies in its sustained-release technology. Its disadvantage is the smaller size and relative lack of experience compared to larger, established competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the launch and increasing adoption of DEXTENZAu00ae.
Future Projections: Future growth is expected to depend on the expansion of DEXTENZAu00ae's label, the development of new pipeline products, and strategic partnerships.
Recent Initiatives: Recent initiatives include clinical trials for new indications, strategic collaborations, and efforts to expand market access for DEXTENZAu00ae.
Summary
Ocular Therapeutix is a biopharmaceutical company with innovative technology and an FDA-approved product, DEXTENZA. The company has the potential for growth through pipeline development and market expansion. However, it faces challenges related to commercialization, competition, and funding. Investors should closely monitor clinical trial results, regulatory developments, and financial performance to assess the company's prospects. The long-term success hinges on its ability to translate its innovative technology into commercially successful products and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and projections are subject to change and may not be accurate. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocular Therapeutix Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2014-07-25 | Executive Chairman, President & CEO Dr. Pravin U. Dugel M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 274 | Website https://www.ocutx.com |
Full time employees 274 | Website https://www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.